Is positron emission tomography enough to rule out cardiac sarcoidosis? A case report

Siyi Huang 1*, Siri Kunchakarra 2, and Ankit Rathod 2

1Internal Medicine, University of California, San Francisco, Fresno, 155 N Fresno St, Fresno, CA 93701, USA; and 2Cardiology, University of California, San Francisco, Fresno, 2335 E Kashian Ln, Fresno, CA 93701, USA

Received 24 January 2021; first decision 31 March 2021; accepted 22 July 2021

Background
Cardiac sarcoidosis (CS) is associated with poor prognosis, yet the clinical diagnosis is often challenging. Advanced cardiac imaging including cardiac magnetic resonance (CMR) and positron emission tomographic (PET) have emerged as useful modalities to diagnose CS.

Case summary
A 66-year-old woman presented with palpitations. A 24-h Holter monitor detected a high premature ventricular contraction burden of 25.6%. She underwent two transthoracic echocardiograms; both showed normal results. Stress perfusion CMR did not show any evidence of ischaemic aetiology; however, myocardial lesions detected by late gadolinium enhancement (LGE) imaging raised suspicion for CS. While there was no myocardial uptake of fluorodeoxyglucose (FDG) in subsequent cardiac PET, high FDG uptake was seen in hilar lymph nodes. Lymph node biopsy confirmed the diagnosis of sarcoidosis.

Discussion
Cardiac magnetic resonance and PET imaging are designed to evaluate different aspects CS pathophysiology. The characteristic LGE in the absence of increased FDG uptake suggested inactive CS with residual myocardial scarring.

Keywords
Cardiac sarcoidosis • Cardiac magnetic resonance • Positron emission tomographic • Case report

Introduction
Sarcoidosis is a granulomatous disease of unknown aetiology that involves multiple organs. Although cardiac involvement is clinically evident in only 5–10% patients with sarcoidosis, myocardial lesions can be identified at autopsy among ~20–60% cases.1 Importantly, patients with cardiac sarcoidosis (CS) appear to suffer from a worse prognosis than those without cardiac involvement.2–4 Early diagnosis and close follow-up are crucial, but the clinical diagnosis of CS is often challenging in reality because of variable and non-specific clinical

Learning points
• Fluorodeoxyglucose positron emission tomography study identifies active myocardium inflammation; however, negative study result cannot completely rule out cardiac sarcoidosis (CS).
• Cardiac magnetic resonance has unique advantages in initial evaluation of CS as it can identify myocardium scar, detect active inflammation and oedema, assess left ventricular function, and exclude ischaemic aetiology in one single exam.

* Corresponding author. Tel: +1 734 358 9291, Email: zoe.siyihuang@gmail.com
Handling Editor: Parham Eshtehardi
Peer-reviewers: Danny van de Sande; Erica Tirr and Zahra Raisi Estabragh
Compliance Editor: Brett Sydney Bernstein
Supplementary Material Editor: Katharine Kott
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
manifestation. Advanced cardiac imaging including cardiac magnetic resonance (CMR) and positron emission tomography (PET) have both emerged as useful non-invasive modalities to detect and diagnose CS. However, each of these techniques has unique advantages and limitations, as they are able to detect different pathological attributes of the disease.

Timeline

| Time       | Events                                                                 |
|------------|------------------------------------------------------------------------|
| Presentation | Presented with palpitations                                               |
| Electrocardiography showed right bundle branch block                  |
| Month 1    | A 24-h Holter monitor showed high premature ventricular contraction burden |
| Month 7    | Transthoracic echocardiogram was normal                                  |
| Month 8    | Cardiac magnetic resonance imaging raised suspicion for cardiac sarcoidosis |
| Month 12   | Positron emission tomography showed high fluorodeoxyglucose uptake in hilar lymph nodes instead of myocardium |
| Month 13   | Mediastinal lymph node biopsy was consistent with sarcoidosis          |

Case presentation

A 66-year-old woman with a medical history of hypertension and diabetes mellitus presented to the cardiology clinic with palpitations. Electrocardiography showed sinus rhythm with right bundle branch block (RBBB). She had an unremarkable transthoracic echocardiogram (TTE) and nuclear stress test 1 year ago as part of the preoperative evaluation for hip surgery. A 24-h Holter monitor detected a high premature ventricular contraction (PVC) burden of 25.6%, with a predominant monomorphic morphology (Figure 1). A repeat TTE at this time showed normal right ventricular and left ventricular systolic function without any signs of regional wall motion abnormality. Given her high PVC burden, she underwent stress perfusion CMR to evaluate potential ischaemic aetiology, along with late gadolinium enhancement (LGE) imaging for myocardial scar assessment. Both ventricular size and systolic function were normal on CMR with an ejection fraction of 60–65%. There was no definite evidence of coronary artery pattern ischaemia on regadenoson stress perfusion test (Video 1). However, LGE detected two myocardial lesions. The first, the subendocardial enhancement, was located at the basal inferolateral wall with <25% of the myocardium segment involved. The second enhancement was noticed within the mid myocardium of the basal inferoseptal wall (Figure 2). There was no definite increased in signal intensity detected by T2 imaging. Non-calculated enlarged hilar lymph nodes were seen on scout images. Cardiac sarcoidosis was considered as a possible diagnosis, and prior myocarditis was another differential diagnosis based on the LGE pattern. The patient underwent cardiac PET with sarcoidosis-specific protocol for further evaluation. Although there was no myocardial uptake of fluorodeoxyglucose (FDG), high FDG uptake was seen in the hilar lymph nodes. The results of PET imaging raised the suspicion of either lymphoma or extracardiac sarcoidosis (Figure 3). The patient subsequently underwent transbronchial biopsy of the mediastinal lymph nodes, which confirmed the presence of non-necrotizing granulomas, suggestive of sarcoidosis.

Figure 1 A 24-h Holter monitor shows a high premature ventricular contraction burden of 25.6%, with a predominant monomorphic morphology.
Discussion

There are three main manifestations of CS: conduction abnormalities; ventricular arrhythmias including sudden death; and heart failure.2,3 In our case, the patient presented with palpitations, RBBB, and frequent monomorphic PVCs. However, none of those findings were specific, which makes diagnosis difficult, especially during the early stage of the disease. Although positive endomyocardial biopsy can confirm CS diagnosis, the diagnostic yield is <20% owing to the focal nature of the disease; hence, it is only indicated in patients with negative extracardiac biopsy result but high suspicion of CS.2 Our patient fulfilled the clinical diagnostic criteria for CS based on the 2014 Heart Rhythm Society (HRS) expert consensus statement, which includes: (i) histological diagnosis of extracardiac sarcoidosis and (ii) LGE on CMR in a pattern consistent with CS.3

Positron emission tomography is widely used in the assessment of CS. 18F-FDG is a glucose analogue taken up by macrophages in active myocardial inflammatory lesions. 18F-FDG PET is helpful to detect myocardial inflammation and can therefore be used to diagnose active CS and monitor response to treatment. Focal and focal-on-diffuse are two characteristic FDG uptake patterns seen in the myocardium.2,6 However, we should be aware that undetected myocardial FDG uptake cannot rule out cardiac involvement, because it only detects active disease, as seen in our patient.

Cardiac magnetic resonance has unique advantages in the initial evaluation of CS, because it can identify detailed tissue

Figure 2  Cardiac magnetic resonance late gadolinium enhancement shows subendocardial enhancement at the basal inferolateral wall with <25% of the myocardium segment involved (red arrows). Patchy mid-myocardial enhancement at the basal inferoseptal wall with <25% of the segment involved (yellow arrows) [(A) long-axis three-chamber view; (B) short-axis at mid-cavity level; (C) long-axis four-chamber view; (D) short-axis view at basal level].
characterization, accurately assess left ventricular wall thickness and function, and exclude ischaemic aetiology by stress perfusion imaging in one single exam. The high resolution of LGE technique allows it to detect small-scale myocardial damage caused by CS at a very early stage. Patel et al. showed that among 81 patients with biopsy-proven extracardiac sarcoidosis, LGE was more than twice as sensitive to identify cardiac involvement as the consensus criteria based on the modified Japanese Ministry of Health (JMH) guidelines. Although there is no specific pathognomonic LGE pattern for CS, it is usually described as patchy and multifocal, along with endocardial-border sparing and a non-coronary distribution. It is most commonly seen in basal segments, especially in the septum and lateral wall.

Additional studies have shown that myocardial scarring in sarcoidosis patients diagnosed by LGE is associated with poor prognosis and is the best independent predictor of adverse and potentially lethal events. In the same study conducted by Patel et al., patients with LGE-detected myocardial damage had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than those without damage. In another study, Gowani et al. followed-up 50 patients for 4.1 years. Late gadolinium enhancement was found to have higher negative predictive value for the development of ventricular arrhythmias than FDG PET (100% vs. 79%). There is growing consensus that CMR should be considered for sudden death risk stratification.

In our case, myocardial lesions detected by LGE were located apart in the basal segments, including the one within the mid-myocardium, sparing the endocardium. This pattern was highly suggestive of non-ischaemic aetiology, which was further supported by normal stress perfusion test. Although myocardium damage from prior myocarditis may also have similar manifestation, the classic enhancement distribution and the lack of viral prodrome symptoms raised high suspicion for CS. Despite a normal myocardium on FDG PET exam, the clinical suspicion prompted further mediastinum lymph node biopsy. The result showed non-necrotizing granulomas consistent with sarcoidosis, which helped confirm the diagnosis of CS based on the 2014 expert consensus recommendations.

This case was challenging to diagnose due to the unexpected cardiac PET findings. The hypermetabolism in the bilateral hilar and posterior mediastinal lymph nodes is classic for sarcoidosis, which was in line with our clinical suspicion. We expected to see focal or focal-on diffuse FDG uptake pattern in the myocardium to diagnose active CS. The characteristic LGE in the absence of increased FDG uptake in the myocardium suggested inactive CS with residual myocardial scarring. Despite suboptimal imaging quality owing to ventricular arrhythmia, this was also supported by the patient’s T2 imaging as it did not show any convincing evidence of active inflammation.

The patient was started on metoprolol succinate with gradually titrating up and her palpitations significantly improved with the treatment.

**Conclusion**

Cardiac magnetic resonance and PET imaging expose different pathophysiologic features of CS. Positron emission tomography scan is useful to detect ongoing inflammation and guide anti-inflammatory therapy, yet the scan alone is not enough to rule out CS as it may miss the inactive phase of the disease. It is reasonable to use CMR as the initial evaluation tool in cases of suspected CS, given its high diagnostic accuracy and prognostic value.

**Lead author biography**

Siyi Huang is a third-year internal medicine resident at the University of California, San Francisco, Fresno Program, USA. She graduated from Shanghai Jiao Tong University, School of Medicine, China in 2016. She has special interest in advanced cardiac imaging. She is currently pursuing cardiology fellowship training.

**Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.
Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: None declared.

Funding: None declared.

References

1. Patel MR, Cawley PJ, Hetnner JF, Klem I, Parker MA, Jaroudi WA et al. Detection of myocardial damage in patients with sarcoidosis. *Circulation* 2009;120:1969–1977.
2. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. *J Am Coll Cardiol* 2016;68:411–421.
3. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvemoy CS et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm* 2014;11:1305–1323.
4. Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN et al. Cardiac sarcoidosis. *Am Heart J* 2009;157:9–21.
5. Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. *Circ Cardiovasc Imaging* 2018;11:e007030.
6. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakae S, Kamigaki M et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. *Eur Heart J* 2005;26:1538–1543.
7. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. *Eur J Nucl Med Mol Imaging* 2008;35:933–941.
8. Greulich S, Deluigi CC, Gloeckler S, Wahl A, Zümm C, Kramer U et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. *JACC Cardiovasc Imaging* 2013;6:501–511.
9. Coleman GC, Shaw PW, Balfour PC Jr, Gonzalez JA, Kramer CM, Patel AR et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. *JACC Cardiovasc Imaging* 2017;10:411–420.
10. Gowani Z, Habibi M, Okada DR, Smith J, Derakhshan A, Zimmerman SL et al. Utility of cardiac magnetic resonance imaging versus cardiac positron emission tomography for risk stratification for ventricular arrhythmias in patients with cardiac sarcoidosis. *Am J Cardiol* 2020;134:123–129.